And the FDA has approved Amgen’s Uplizna for adults with antibody-positive generalized myasthenia gravis, adding a ...
This pilot project evaluated whether targeted training could strengthen clinical research capacity at community cancer centers, improve readiness to conduct oncology trials, and support more inclusive ...
Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...
See how combining human oversight with AI insights improves protocol authorship, site selection, and monitoring strategies, ...
New data show that applying AI to the migration of translated COAs into eCOA platforms can meaningfully reduce errors, accelerate localization workflows, and support broader global patient ...
In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global ...
In today’s ACT Brief, we highlight new insights from McKinsey on where AI can meaningfully accelerate clinical development, break down the emerging design and regulatory forces reshaping obesity drug ...
Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...
In today’s ACT Brief, we explore how stronger vendor–sponsor governance is speeding eCOA study startup, hear from AMR ...
As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...
As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...
As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback